CTAG1A, cancer/testis antigen 1A, 246100

N. diseases: 161; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0278660
Disease: Adult Synovial Sarcoma
Adult Synovial Sarcoma
0.080 Biomarker disease BEFREE Beyond its role in patient selection for targeted therapy, immunohistochemistry for NY-ESO-1 may be diagnostically useful for the distinction of synovial sarcoma from other spindle cell neoplasms. 22388761 2012
CUI: C0278660
Disease: Adult Synovial Sarcoma
Adult Synovial Sarcoma
0.080 Biomarker disease BEFREE CMB305 also includes a boost from a NY-ESO-1 protein vaccine given along with a potent toll-like-4 receptor agonist, glycopyranosyl lipid A. CMB305 induces NY-ESO-1 specific T cell responses in both SS and MRC patients and these patients had excellent overall survival (OS) outcomes in the initial phase I study. 29280411 2018
CUI: C0278660
Disease: Adult Synovial Sarcoma
Adult Synovial Sarcoma
0.080 Biomarker disease BEFREE Among the up-regulated cancer-testis antigens, we analyzed PRAME, MAGEA1, and MAGEA4 and another cancer-testis antigen (NY-ESO-1) together, by immunohistochemistry and real-time polymerase chain reaction in 108 SSs. 27993576 2017
CUI: C0278660
Disease: Adult Synovial Sarcoma
Adult Synovial Sarcoma
0.080 Biomarker disease BEFREE Combined use of MAGEA4 and NY-ESO-1 increased the sensitivity, specificity, positive predictive values, and negative predictive values for distinguishing synovial sarcoma from spindle cell tumors and other mimicking tumors, compared to individual use of MAGEA4 or NY-ESO-1. 28744588 2017
CUI: C0278660
Disease: Adult Synovial Sarcoma
Adult Synovial Sarcoma
0.080 Biomarker disease BEFREE Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 <sup>c259</sup>T Cells in Synovial Sarcoma. 29891538 2018
CUI: C0278660
Disease: Adult Synovial Sarcoma
Adult Synovial Sarcoma
0.080 Biomarker disease BEFREE These results indicate that NY-ESO-1 and MAGE-A4 may be useful for the diagnosis of synovial sarcoma. 30881511 2019
CUI: C0278660
Disease: Adult Synovial Sarcoma
Adult Synovial Sarcoma
0.080 Biomarker disease BEFREE Although SS has failed to respond to immune checkpoint blockade, other strategies designed to generate an immune response, including adoptive cell therapies targeting the cancer testis antigen NY-ESO-1, have shown encouraging results. 30076141 2018
CUI: C0278660
Disease: Adult Synovial Sarcoma
Adult Synovial Sarcoma
0.080 AlteredExpression disease BEFREE Finally, in regard to the investigation of cancer-testis antigens, myxoid/round cell liposarcoma and synovial sarcoma showed frequent and high expression of PRAME and NY-ESO-1. 28759137 2017